The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2005Validating Toxic Protein Aggregation as a Therapeutic Target in PD (2)
The aggregation/fibrillation of the presynaptic protein alpha-synuclein is a key factor in the development of Parkinson’s disease. There is a critical need for an effective treatment of Parkinson’s...
-
Target Validation, 2005Screening of Small Molecule Libraries to Identify Trace Amine Receptor Ligands Active in Treatment of PD
For the treatment of Parkinson’s disease, no direct dopamine agonist compares in efficacy to levodopa, suggesting that levodopa itself or its metabolites may affect targets in addition to dopamine...
-
Target Validation, 2005Inhibitors of Poly (ADP-Ribose) Glycohydrolase (PARG) as Novel Agents for the Treatment of PD
It has become increasingly clear that the death of mid-brain neurons in Parkinson's disease patients is associated with the activation of certain enzymes that add sugar units onto various proteins. In...
-
Clinical Discovery Awards, 2005Phase I Study of CERE-120 [Adeno-Associated Virus (AAV)-Neuturin (NTN)] to Assess the Safety and Tolerability of Intraputaminal Delivery
Objective/Rationale:
Neurotrophic factors including neurturin (NTN) have been shown to effectively augment the function and prevent the death of dopaminergic nigrostriatal neurons in animal models of... -
MJFF Research Grant, 2006A Phase II Clinical Trial of Neurturin (NTN) Gene Therapy for PD
Objective/Rationale:
Neurotrophic factors including neurturin (NTN) have been shown to effectively augment the function and prevent the death of dopaminergic nigrostriatal neurons in animal models of... -
MJFF Research Grant, 2006The Unified Dyskinesia Rating Scale (UDysRS): Clinimetric Testing Program
In Parkinson’s disease, one of the most troubling clinical issues for prevention and management is drug-induced dyskinesia. Dyskinesias are abnormal and involuntary movements that relate in part to...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.